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Neurofibromatosis type 1 (NF1) is the most prevalent autosomal dominant genetic disorder among humans. NF1
vasculopathy is a significant but underrecognized complication of the disease, affecting both arterial and venous
blood vessels of all sizes. Moyamoya syndrome is a cerebral vasculopathy that is only rarely observed in association
with NF1, particularly in the pediatric age range. Herein, we report of a 5-year-old female with NF1 and moyamoya
syndrome and we briefly review the existing literature.
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ChildhoodIntroduction
Neurofibromatosis type 1 (NF1) or von Recklinghausen
is the most common neurocutaneous contidion with an
autosomal dominant pattern of inheritance. 1/3 of cases
are new mutations [1]. This genetic disorder caused by
mutations of the NF1 gene which is located on chromo-
some 17(17q11.2) [1]. Patients with NF1 may present
with a variety of central nervous system complaints, such
as seizures, learning disability and attention-deficit disorder.
Intracranial lesions associated with NF1 include optic gli-
omas, sphenoid wing dysplasia, “unidentified bright objects”
(UBOs) [1,2]. Cerebrovascular lesions such as moyamoya
syndrome are rarely seen in NF1 [2]. Herein, we report of a
5-year-old female with NF1 and moyamoya syndrome and
we briefly review the existing literature.Case report
A 5 year-old female was admitted to the hospital with a
history of acute right-sided weakness. The physical
examination revealed several café-au-lait spots (larger
than 0.5 cm) and freckling in the inguinal area and the
axillae, thus fulfilling diagnostic criteria for NF1 [1,2].
The neurologic examination demonstrated right spas-
tic hemiplegia with increased muscle tone of upper
and low extremities, increased tendon reflexes as well
as right facial nerve palsy.* Correspondence: jeff@med.auth.gr
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vestigations, complete blood cell count, blood biochem-
istry, radiographs of long bones, electroencephalogram,
visual and brainstem auditory evoked potentials, echo-
cardiography, abdominal ultrasound and ophthalmologic
examination were normal. Brain magnetic resonance
imaging (MRI) of the brain, showed multiple small foci
of T2 prolongation in the right periventricular white
matter, as well as both globus pallidi and cerebellar
hemispheres (“unidentified bright objects” -UBOs). These
lesions were hypointense on T1-weighted images, did not
show any mass effect, and did not enhance after intraven-
ous contrast injection (Figure 1). Also, multiple dot-like
flow-void enhancing areas in basal gaglia and thalamus
representing lenticulostriade collateral vessels were seen
(Figure 2).
Magnetic resonance angiography of the brain (MRA)
(and subsequent digital subtraction angiography), showed
occlusion of the terminal left internal carotid artery (ICA)
and severe stenosis of the proximal middle and anterior
cerebral arteries, with multiple tiny basal collateral arteries
(Figure 3). Anterior circulation was supplied mainly by
these lenticulostriate and thalomo-perforator collaterals
vessels. The right ICA and the posterior circulation were
normal. These findings were considered as typical for
moyamoya syndrome. Additional examinations included
clotting, thrombophilia screen, iron and folate screen, dem-
onstrated normal findings.
After neurosurgical consultation, surgical revasculari-
sation [namely a left encephalo-duroarterio-synangiosisal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Brain MRI: T2-weighted images (TR/TE 4000/99) showed pathologic areas of increased signal, a. in right basal ganglia (UBO’S), b. Iin
the deep white matter of cerebellum, c. in corpus callosum demonstrated typical areas of UBO’S (unidentified bright objects) in NF 1 disease.
Figure 2 Brain MRI: T2-weighted images (TR/TE 4000/99) showed
multiple sites empty signal mainly in the left basal ganglia and
ipsilateral lunate center in as in the presence of collateral vessels.
Vargiami et al. Italian Journal of Pediatrics 2014, 40:59 Page 2 of 6
http://www.ijponline.net/content/40/1/59(EDAS)], was carry out electively. The intraoperative and
postoperative course was unremarkable. Treatment with
aspirin was immediately started and physical and occupa-
tional therapy was initiated. At 2-years follow-up her facial
weakness had resolved (since 6 months postoperative),
but still demonstrates a mild right hemiparesis.
Discussion
NF1 is multisystemic disease, which affect the skin, central
nervous system and bone system [1,2]. Its diagnosis is
based on the clinical criteria established by the National In-
stitutes of Health (NIH) Consensus Development Confer-
ence [3]. For a definitive diagnosis of NF-1, two or more of
the following clinical characteristics must be present, six or
more café-au-lait spots with a diameter more than 5 mm,
two or more neurofibromas, axillary or inguinal freckling,
one reticular neurofibroma, two or more Lisch nodules
(hamartomas), an optic glioma, skeletal abnormalities, such
as sphenoid dysplasia or pseudarthrosis of the tibia and first
degree relationship with a patient suffering from NF1 [3].
These criteria are not sensitive to very young children, since
many of them may appear gradually over the years, while
children over 10 years old who do not meet the criteria are
unlikely to suffer from NF1 [3].
NF1 vasculopathy is a significant but under-recognized
complication of the disease, affecting arterial and venous
Figure 3 MR angiography of the brain (MRA): virgate imaging
petrous segment and the proximal portion of the left internal
carotid artery and occlusion of the distal vessel.
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most commonly affected, venous circulation may also be
involved [2]. A variety of vascular lesions have been noted
in patients with NF1, including occlusion, aneurysm, pseu-
doaneurysm, ectasia, stenosis, fistula and rupture [4,5]. Ac-
cording to bibliographic data, the internal carotid artery is
most commonly affected, followed by middle and posterior
cerebral artery. Although rare in childhood, there was ex-
tracranial vascular involvement mainly in the renal artery
[5]. The main characteristic of vascular lesions in patients
with NF-1 is occlusion of the lumen and hyperplasia of the
intima wall. Based on microscopic evaluation of the affected
vessels, it has been proposed that the vasculopathy of NF-1
patients results from abnormal neurofibromin function
that leads to excessive proliferation of vascular smooth
muscle cells during normal maintenance of the vessel.
Conversely, even though neurofibromin is known to be
expressed in vascular smooth muscle cells, little is
known about its function relating to controlling endo-
thelial cell proliferation [2,5,6].
The precise mechanisms involved in NF1, the patho-
genesis of vasculopathy are poorly understood but are likely
related to the function of neurofibromin, the protein prod-
uct of the NF1 gene [6]. Neurofibromin has been identified
in the endothelial layer of bovine and rodent cerebral and
renal arteries, as well as the aorta. It has been hypothesized
that the loss of neurofibromin expression in endothelial
cells may somehow cause vascular smooth muscle cells to
proliferate [6]. It has also been suggested that neurofibro-
min helps maintain the integrity of the endothelial cell layer,
and if this integrity is lost because of aberrant neurofibro-
min, vascular smooth muscle cells could proliferate [2,6].
Moyamoya syndrome is a rare disorder developing by
stenosis and occlusion of small anastomotic vessels indistal branches of bilateral internal carotid arteries
[7,8]. Nonetheless, its etiology continues to be ill-
defined. Moyamoya syndrome is more frequently ob-
served in the Japanese population, with an estimated
incidence of one new case per 1,000,000 individuals
per year [7]. The clinical findings present with neuro-
logical symptoms, whereas ischemic stroke develops in
young adults, subarachnoid hemorrhage develops in
older patients in moyamoya syndrome [7].
The prevalence of moyamoya syndrome in NF1 pa-
tients is estimated at 0.6%, with more than one hundred
cases reported in paediatric patients since 1976 (Table 1)
[8-43]. Moyamoya syndrome in patients with NF1 is
often initially unilateral and often involves anterior vas-
cular territories [43]. Most cases are asymptomatic, how-
ever, subsequent clinical and radiologic worsening is
likely to occur [40-43]. In children, the clinical debut
often implies ischemic events, such as transient ischemic
attacks and ischemic infarcts, as well as focal seizures
with headache, and intracranial hemorrhage might also
be associated [40-43]. When symptoms are present, they
include neurological findings such as paresthesia, head-
ache, epileptic seizures, hemianopsia, nystagmus, apha-
sia, dysphasia and borderline mental level [16,40-43].
There are several lines of evidence indicating that
moyamoya syndrome is related to genetic factors in fa-
milial cases. The gene abnormality has been detected
in chromosome 17q25.2 [44]. NF1 gene is also mapped
on chromosome 17q11.2 [2]. Hence, association of
NF1 and moyamoya syndrome could be justified by
close proximity neighboring of the responsible genes
on chromosome 17 [10]. Moyamoya syndrome in NF1
patients is unilateral in up to 30% of cases, but the observa-
tion that progression to bilateral disease occurs in 10%–
100% of these patients means that our patient may require
long-term surveillance, and noninvasive perfusion studies
may be helpful for assessment [9,45].
The diagnosis of moyamoya syndrome based on neuro-
imaging control. In patients with moyamoya syndrome, the
brain computed tomography (CT) scan frequently shows
ischemic and hemorrhagic lesions, although MRI is more
helpful in the diagnosis of moyamoya syndrome because
the provide greater parenchymal detail [46]. MRA is very
useful for diagnosing moyamoya syndrome, with previous
studies showing a sensitivity of 73% and a specificity of
100%. Sensitivity increases to 92% when MRA is combined
with MRI findings [46]. The diagnosis of moyamoya syn-
drome in our patient was supported with MRI and MRA,
which is standard practice in our clinical routine screening
of children with NF1.
Most patients with NF-1 associated with vascular lesions
are asymptomatic. Early diagnosis and appropriate surgical
management are of utmost importance, to improve cerebral
hemodynamics and reduce the incidence of subsequent
Table 1 Moyamoya syndrome in NF1 paediatric patients since 1976
Authors Year Study N (patients) Age Patients with
moyamoya-NF1
Duat-Rodríguez A et al. [42] 2014 Retrospective review 168 4
Partha S. G et al. [40] 2013 Retrospective review 312 7
Kaas B et al. [43] 2013 Retrospective review 187 5
Ghosh, P. S., et al. [10] 2012 398 15/312 (4,8%)
Luiz G D et al. [41] 2011 Case report 1 8 months 1
Ullrich, N. J. [11] 2011 Case report 1
Smith, M [12] 2011 Case report 18 m boy 1
Lin, N., et al. [13] 2011 Retrospective review 1988-2010 418 9.1y (1-21y) 13
Horiguchi, S., et al. [14] 2011 Case report 1 32y 1
Darrigo Junior, et al. [15] 2011 Case report 8 m female 1
King, J. A., et al. [16] 2010 Retrospective review
(May 1996-December 2008)
33 < 16y 3
Tan, R. M., S. M. Chng, et al. [17] 2008 Case report 1 7y female 1
Koc, F., et al. [18] 2008 Case report 1 20y female 1
Borhani-Haghighi, A. and B. Sabayan [19] 2008
Wintermark, P., et al. [20] 2007 Case report 1
Ullrich, N. J., et al. [21] 2007
Pascual-Castroviejo, I., et al. [22] 2006 12 1
Desai, S. S., et al. [23] 2006 Review 1967-2002 54 14
Fujimura, T., et al. [24] 2004 Case report 15y female
Scott, R. M., J. L. Smith, et al. [41] 2004 Retrospective review 143 <20y 13
Hug, E. B., et al.[25] 2002 Retrospective review Sep 1991-Aug 1997 27 1
El-Koussy, M., et al. [26] 2002 Case report 1
Rodriguez-Jadraque, R., et al. [27] 2000 Case report 9y 1
Serdaroglu, A., et al. [20] 2000 Case report 4y female 1
Piovesan, E. J., et al. [28] 1999 Case report 51y 1
Fujimoto, K., et al. [29] 1999 Case report 49y female 1
Siqueira Neto, J. I., et al. [30] 1998 Case report 28y male 1
Hattori, S., et al. [31] 1998 Case report 58y female 1
Barrall, J. et al. [32] 1996 Case report 19 m male 1
Gorrotxategi, P., et al. [33] 1994 Case report 4y male 1
Kestle, J. R., et al. [34] 1994 Retrospective review 1971-1990 47 3
Woody, R. C., et al. [35] 1992 Case report 1 3 m male 1
Sobata, E., H. Ohkuma, et al. [36] 1988 Case report 1 28y female 1
Gracia, C. M., et al. [37] 1986 Case report 1 33y female 1
Quest, D. O. et al. [38] 1985 Retrospective review 17 1
Sasaki, O., et al. [39] 1984 Case report 2 38y male 2
29y female
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abnormalities is warranted because the long-term out-
come of these vascular lesions is unknown. Moreover,
early recognition of a cerebral vasculopathy may have
helped prevent complications in several of these chil-
dren [8,47,48].Surgical intervention has become the treatment of
choice for patients with MMS, and particularly surgical revas-
cularization in order to increase the blood flow to the hypo-
perfused cortex [49-51]. On the index patient, the surgical
procedure of choice was EDAS (encephaloduroarteriosynan-
giosis) and resulted in no further symptoms or brain insults.
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http://www.ijponline.net/content/40/1/59In conclusion, vasculopathy in NF1 is a potentially ser-
ious and underestimated manifestation. MRA screening
could be helpful in identified early vascular lesions in
asymptomatic NF1 patients. Further studies are needed,
in large cohorts of NF1 patients, to better understand
the association between these conditions.
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